Global Diabetic Neuropathy Drugs Market 2019-2023

糖尿病性神経障害薬の世界市場2019-2023

◆タイトル:Global Diabetic Neuropathy Drugs Market 2019-2023
◆商品コード:IRTNTR31087
◆調査・発行会社:Technavio (Infiniti Research Ltd.)
◆発行日:2019年3月28日
◆ページ数:135
◆資料形式:PDF / 英語
◆納品方法:Eメール(受注後24時間以内)
◆調査対象地域:グローバル、アジア、北米、ヨーロッパ(EMEA)
◆産業分野:医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD2,500 ⇒換算¥272,500見積依頼/購入/質問フォーム
Five User(5名様閲覧用)USD3,000 ⇒換算¥327,000見積依頼/購入/質問フォーム
Enterprise License(同一法人内共有可)USD4,000 ⇒換算¥436,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※商品の納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。(振込先:三菱東京UFJ銀行/京橋支店/H&Iグローバルリサーチ株式会社)
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※ご購入後、資料に記載の英語表現や単語の意味に関しましては無料でお答えいたします。(但し、対応範囲は弊社で判断)
※弊社H&Iグローバルリサーチ株式会社はTechnavio (Infiniti Research Ltd.)の日本における正規販売代理店です。

【資料の概要】

当調査レポートでは、糖尿病性神経障害薬の世界市場について調査・分析し、市場概要、市場環境、糖尿病性神経障害薬市場規模、作用機序別(カルシウムチャネルアルファ-2-デルタリガンド、SNRIs及びTCAs、その他)分析、市場動向、競争環境、主要地域別市場規模(北米、ヨーロッパ、アジアなど)、関連企業情報などを含め、以下の構成でお届け致します。
・エグゼクティブサマリー
・調査範囲・調査手法
・糖尿病性神経障害薬の世界市場概要
・糖尿病性神経障害薬の世界市場環境
・糖尿病性神経障害薬の世界市場動向
・糖尿病性神経障害薬の世界市場規模
・糖尿病性神経障害薬の世界市場:業界構造分析
・糖尿病性神経障害薬の世界市場:作用機序別(カルシウムチャネルアルファ-2-デルタリガンド、SNRIs及びTCAs、その他)
・糖尿病性神経障害薬の世界市場:地域別市場規模・分析
・糖尿病性神経障害薬の北米市場規模・予測
・糖尿病性神経障害薬のヨーロッパ・中東・アフリカ市場規模・予測
・糖尿病性神経障害薬のアジア太平洋市場規模・予測
・糖尿病性神経障害薬の主要国分析
・糖尿病性神経障害薬の世界市場:意思決定フレームワーク
・糖尿病性神経障害薬の世界市場:成長要因、課題
・糖尿病性神経障害薬の世界市場:競争環境
・糖尿病性神経障害薬の世界市場:関連企業情報(ベンダー分析)

About this market
The rising awareness about diabetic neuropathy is one of the prominent factors likely to contribute to the diabetic neuropathy drugs market growth in the forthcoming years. Several awareness programs are being launched among the consumers with an aim to educate and train diabetes educators in the emerging and advanced economies. Different campaigns are encouraging people to take an online test for knowing about the risk factors associated with prediabetes, in turn, driving the diabetic neuropathy drugs market growth during the forecast period. Technavio’s analysts have predicted that the diabetic neuropathy drugs market will register a CAGR of about 6% by 2023.
Market Overview
New drug approvals and strong drug pipeline
One of the growth drivers of the global diabetic neuropathy drugs market is new drug approvals and strong drug pipeline. With the rising prevalence of diabetic neuropathy, several market players are focusing on the development of disease-modifying drugs to treat the disease.
Side-effects of major drugs
One of the challenges in the growth of the global diabetic neuropathy drugs market is the side-effects of major drugs. Side-effects associated with approved drugs such as pregabalin (LYRICA) and gabapentin (NEURONTIN) can lead to low patient compliance, thereby hindering the growth of the market.
For the detailed list of factors that will drive and challenge the growth of the diabetic neuropathy drugs market during 019-2023, view our report.
Competitive Landscape
The market appears to be moderately fragmented with the presence of several market players. Vendors in the market are focusing on the development of novel biologics to treat diabetic neuropathy. This market research report will help clients identify new growth opportunities and design unique growth strategies by providing a comprehensive analysis of the market’s competitive landscape and offering information on the products offered by companies.

【資料の目次】

PART 01: EXECUTIVE SUMMARY
PART 02: SCOPE OF THE REPORT
• 2.1 Preface
• 2.2 Preface
• 2.3 Currency conversion rates for US$
PART 03: MARKET LANDSCAPE
• Market ecosystem
• Market characteristics
• Market segmentation analysis
PART 04: MARKET SIZING
• Market definition
• Market sizing 2018
• Market size and forecast 2018-2023
PART 05: FIVE FORCES ANALYSIS
• Bargaining power of buyers
• Bargaining power of suppliers
• Threat of new entrants
• Threat of substitutes
• Threat of rivalry
• Market condition
PART 06: CUSTOMER LANDSCAPE
PART 07: GEOGRAPHIC LANDSCAPE
• Geographic segmentation
• Geographic comparison
• North America – Market size and forecast 2018-2023
• Europe – Market size and forecast 2018-2023
• Asia – Market size and forecast 2018-2023
• ROW – Market size and forecast 2018-2023
• Key leading countries
• Market opportunity
PART 08: MARKET SEGMENTATION BY MECHANISM OF ACTION
• Market segmentation by mechanism of action
• Comparison by mechanism of action
• Calcium channel alpha-2-delta ligand – Market size and forecast 2018-2023
• SNRIs and TCAs – Market size and forecast 2018-2023
• Others – Market size and forecast 2018-2023
• Market opportunity by mechanism of action
PART 09: DRIVERS AND CHALLENGES
• Market drivers
• Market challenges
PART 10: MARKET TRENDS
• Market trends
PART 11: VENDOR LANDSCAPE
• Overview
• Landscape disruption
• Competitive scenario
PART 12: VENDOR ANALYSIS
• Vendors covered
• Vendor classification
• Market positioning of vendors
• DAIICHI SANKYO COMPANY, LIMITED
• Eli Lilly and Company
• Johnson & Johnson Services, Inc.
• Novartis AG
• Pfizer Inc.
PART 13: APPENDIX
• Research methodology
• List of abbreviations


Exhibit 01: Years in consideration
Exhibit 02: Global pharmaceuticals market
Exhibit 03: Segments of global pharmaceuticals market
Exhibit 04: Market characteristics
Exhibit 05: Market segments
Exhibit 06: Market definition – Inclusions and exclusions checklist
Exhibit 07: Market size 2018
Exhibit 08: Global market: Size and forecast 2018-2023 ($ millions)
Exhibit 09: Global market: Year-over-year growth 2019-2023 (%)
Exhibit 10: Five forces analysis 2018
Exhibit 11: Five forces analysis 2023
Exhibit 12: Bargaining power of buyers
Exhibit 13: Bargaining power of suppliers
Exhibit 14: Threat of new entrants
Exhibit 15: Threat of substitutes
Exhibit 16: Threat of rivalry
Exhibit 17: Market condition – Five forces 2018
Exhibit 18: Customer landscape
Exhibit 19: Market share by geography 2018-2023 (%)
Exhibit 20: Geographic comparison
Exhibit 21: North America – Market size and forecast 2018-2023 ($ millions)
Exhibit 22: North America – Year-over-year growth 2019-2023 (%)
Exhibit 23: Europe – Market size and forecast 2018-2023 ($ millions)
Exhibit 24: Europe – Year-over-year growth 2019-2023 (%)
Exhibit 25: Asia – Market size and forecast 2018-2023 ($ millions)
Exhibit 26: Asia – Year-over-year growth 2019-2023 (%)
Exhibit 27: ROW – Market size and forecast 2018-2023 ($ millions)
Exhibit 28: ROW – Year-over-year growth 2019-2023 (%)
Exhibit 29: Key leading countries
Exhibit 30: Market opportunity
Exhibit 31: Mechanism of action – Market share 2018-2023 (%)
Exhibit 32: Comparison by mechanism of action
Exhibit 33: Calcium channel alpha-2-delta ligand – Market size and forecast 2018-2023 ($ millions)
Exhibit 34: Calcium channel alpha-2-delta ligand – Year-over-year growth 2019-2023 (%)
Exhibit 35: SNRIs and TCAs – Market size and forecast 2018-2023 ($ millions)
Exhibit 36: SNRIs and TCAs – Year-over-year growth 2019-2023 (%)
Exhibit 37: Others – Market size and forecast 2018-2023 ($ millions)
Exhibit 38: Others – Year-over-year growth 2019-2023 (%)
Exhibit 39: Market opportunity by mechanism of action
Exhibit 40: Decision framework
Exhibit 41: Pipeline drugs for diabetic neuropathy
Exhibit 42: Impact of drivers and challenges
Exhibit 43: Biologics under development
Exhibit 44: Vendor landscape
Exhibit 45: Landscape disruption
Exhibit 46: Vendors covered
Exhibit 47: Vendor_analysis1
Exhibit 48: Vendor classification
Exhibit 49: Market positioning of vendors
Exhibit 50: DAIICHI SANKYO COMPANY, LIMITED – Vendor overview
Exhibit 51: DAIICHI SANKYO COMPANY, LIMITED – Business segments
Exhibit 52: DAIICHI SANKYO COMPANY, LIMITED – Organizational developments
Exhibit 53: DAIICHI SANKYO COMPANY, LIMITED – Geographic focus
Exhibit 54: DAIICHI SANKYO COMPANY, LIMITED – Segment focus
Exhibit 55: DAIICHI SANKYO COMPANY, LIMITED – Key offerings
Exhibit 56: Eli Lilly and Company – Vendor overview
Exhibit 57: Eli Lilly and Company – Business segments
Exhibit 58: Eli Lilly and Company – Organizational developments
Exhibit 59: Eli Lilly and Company – Geographic focus
Exhibit 60: Eli Lilly and Company – Segment focus
Exhibit 61: Eli Lilly and Company – Key offerings
Exhibit 62: Johnson & Johnson Services, Inc. – Vendor overview
Exhibit 63: Johnson & Johnson Services, Inc. – Business segments
Exhibit 64: Johnson & Johnson Services, Inc. – Organizational developments
Exhibit 65: Johnson & Johnson Services, Inc. – Geographic focus
Exhibit 66: Johnson & Johnson Services, Inc. – Segment focus
Exhibit 67: Johnson & Johnson Services, Inc. – Key offerings
Exhibit 68: Novartis AG – Vendor overview
Exhibit 69: Novartis AG – Business segments
Exhibit 70: Novartis AG – Organizational developments
Exhibit 71: Novartis AG – Geographic focus
Exhibit 72: Novartis AG – Segment focus
Exhibit 73: Novartis AG – Key offerings
Exhibit 74: Pfizer Inc. – Vendor overview
Exhibit 75: Pfizer Inc. – Business segments
Exhibit 76: Pfizer Inc. – Organizational developments
Exhibit 77: Pfizer Inc. – Geographic focus
Exhibit 78: Pfizer Inc. – Segment focus
Exhibit 79: Pfizer Inc. – Key offerings
Exhibit 80: Validation techniques employed for market sizing
Exhibit 81: List of abbreviations



【掲載企業】

DAIICHI SANKYO COMPANY, LIMITED, Eli Lilly and Company, Johnson & Johnson Services, Inc., Novartis AG, Pfizer Inc.

【免責事項】
※当資料上の情報/データは調査会社が信頼できると判断した情報源から入手したものに基づき作成しましたが、その正確性・完全性を保証するものではありません。当資料に記載された情報/データ/見解/仮説などは作成時点又は発行時点における調査会社の判断であり、その後の状況変化に応じて変更される場合があります。当資料上の情報/データに基づいたお客様の意思決定又は実行による結果について、調査会社/発行会社/販売会社H&Iグローバルリサーチはその責を負いかねますのでご了承ください。英文資料の紹介ページにおける日本語題名/概要/目次はH&Iグローバルリサーチが翻訳した内容であり、翻訳の正確性・完全性を保証するものではありません。

[糖尿病性神経障害薬の世界市場2019-2023]についてメールでお問い合わせはこちら


◆H&Iグローバルリサーチ株式会社のお客様(例)◆